Raymond W. Cohen

Mr. Cohen was appointed to the Board of Directors in July 2025. He brings more than 40 years of leadership experience in the medical technology industry with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions.

Mr. Cohen was the Chief Executive Officer and co-founder of Axonics, Inc., which he took public in 2018 and led through its $3.7 billion acquisition by Boston Scientific in 2024. Under his leadership, Axonics was recognized as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021. Until May 2025, he also served as Chairman of SoniVie Ltd., a clinical-stage company developing device treatments for hypertension, which was acquired by Boston Scientific for $600 million.

Previously, Mr. Cohen served as Chief Executive Officer of Vessix Vascular, Inc., where he led the company through its acquisition by Boston Scientific in 2012, and of publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators later acquired by Zoll Medical.

In addition to his executive roles, Mr. Cohen currently serves as an independent director for Kestra Medical (Nasdaq: KMTS) and Spectrum Vascular Inc., as well as Chairman of privately held Nalu Medical and Vice Chairman of privately held Tulavi, Inc.

Mr. Cohen’s career achievements have earned him numerous honors, including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio.